Endocrine Abstracts

Background: Graves’ orbitopathy (GO) is the major extrathyroidal manifestation of Graves’ disease (GD). Even if usually mild and non-progressive, in its worst forms, GO can represent a major therapeutic challenge, because is not always responsive to the available medical treatments. First line treatment for moderate-to-severe and active GO relies on intravenous (i.v.) methylprednisolone. Optic neuropathy is a sight-threatening complication which can seriously impact ...